Dynavax Technologies Corp (DVAX) Q3 2024 Earnings Call Highlights: Record Hep B Sales and ... [Yahoo! Finance]
Dynavax Technologies Corporation (DVAX)
Last dynavax technologies corporation earnings: 3/11 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.dynavax.com
Company Research
Source: Yahoo! Finance
Gross Margin: Improved to 84% in Q3 2024 and 82% for the first nine months of 2024. Net Income: $18 million for Q3 2024. Cash and Equivalents: Approximately $764 million at the end of Q3 2024. Full Year Revenue Guidance: Narrowed to $265 to $270 million for Hep B net product revenue in 2024. R&D Expenses: $14 million for Q3 2024. SG&A Expenses: $43 million for Q3 2024, up from $38 million in Q3 2023. Share Repurchase Plan: $200 million authorized by the board. Warning! GuruFocus has detected 3 Warning Sign with DVAX. Release Date: November 07, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Dynavax Technologies Corp ( NASDAQ:DVAX ) reported record net product sales of $79 million for Hep B in the third quarter. The company achieved a 44% market share in the US for Hep B, up from 41% in the same period last year. Dynavax Technologies Corp ( NASDAQ:DVAX ) has authorized a $200 million share repurchase plan
Show less
Read more
Impact Snapshot
Event Time:
DVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DVAX alerts
High impacting Dynavax Technologies Corporation news events
Weekly update
A roundup of the hottest topics
DVAX
News
- Uvax Bio Announces Interim Results from a Phase 1 Clinical Trial Evaluating its HIV-1 Vaccine [Yahoo! Finance]Yahoo! Finance
- Dynavax Technologies Corporation (DVAX): This Small-Cap Stock Is Ready To Explode [Yahoo! Finance]Yahoo! Finance
- Dynavax Announces $100 Million Accelerated Share Repurchase ProgramPR Newswire
- Dynavax Technologies Corporation Just Recorded A 9.1% EPS Beat: Here's What Analysts Are Forecasting Next [Yahoo! Finance]Yahoo! Finance
- Dynavax Technologies Co. (NASDAQ: DVAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $29.00 price target on the stock.MarketBeat
DVAX
Earnings
- 11/7/24 - Beat
DVAX
Sec Filings
- 11/14/24 - Form SC
- 11/12/24 - Form SC
- 11/12/24 - Form 8-K
- DVAX's page on the SEC website